In conclusion, our preclinical investigation in human CS yields important findings on the potential of RGD4C.PDP to overcome the limitations of TRAIL in cancer therapy paving the way toward targeted systemic therapy with TRAIL in CS patients. This evidence concerns the gene PDP1 and cancer.